{"id":"W4389220803","doi":"10.1182/blood-2023-174510","title":"3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Fludarabine; Chemotherapy regimen; Phases of clinical research; International Prognostic Index; Regimen; Diffuse large B-cell lymphoma; Interim analysis; Surgery; Oncology; Lymphoma; Cyclophosphamide; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007988826,0.001054489,0.002075357,0.0008314846,0.0005146114,0.001907226,0.0009935654,0.001478675,0.003636574],"category_scores_gemma":[0.003550459,0.0005546427,0.003340495,0.00090212,0.0005585058,0.001323595,0.0007257572,0.003204377,0.0008941304],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001321635,"about_ca_system_score_gemma":0.001665219,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001397145,"about_ca_topic_score_gemma":0.003250107,"domain_scores_codex":[0.9980249,0.0008507491,0.0001159881,0.0003476529,0.0003693574,0.0002912735],"domain_scores_gemma":[0.9959471,0.000741638,0.001359672,0.000345201,0.0004422968,0.001164246],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6332192,0.01541234,0.1510783,0.002103232,0.02296048,0.0006957148,0.0004265325,0.008225963,0.01755832,0.0006049368,0.01632249,0.1313926],"study_design_scores_gemma":[0.2005998,0.1965089,0.5486479,0.0002909991,0.02134791,0.001592542,0.000246392,0.007318661,0.004883907,0.0009718919,0.01740997,0.0001810691],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9668362,0.01094499,0.001688838,0.0008373554,0.0001267955,0.0014381,0.01417743,0.0002116601,0.003738689],"genre_scores_gemma":[0.9617113,0.002755821,0.00139365,0.001592558,0.0001563171,0.001251008,0.02829482,0.00007952696,0.002765056],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007988826,"threshold_uncertainty_score":0.04224944,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01785151884795993,"score_gpt":0.2935026324855429,"score_spread":0.275651113637583,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}